Trials / Completed
CompletedNCT03515980
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Participants With Varying Degrees of Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.
Conditions
- Liver Dysfunction
- Liver Insufficiency
- Hepatic Failure
- Myocardial Failure
- Cardiac Failure
- Congestive Heart Failure
- Heart Decompensation
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986231 | Intravenous (IV) administration |
Timeline
- Start date
- 2018-05-25
- Primary completion
- 2019-08-29
- Completion
- 2019-08-29
- First posted
- 2018-05-04
- Last updated
- 2020-08-27
Locations
4 sites across 2 countries: Hungary, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03515980. Inclusion in this directory is not an endorsement.